Plasma Exchange Therapy Cuts Biological Age by 2.6 Years in Clinical Trial
A first-of-its-kind trial shows therapeutic plasma exchange plus IVIG reduced biological age by an average of 2.6 years, confirmed by multi-omics analysis.
Summary
Researchers at the Buck Institute conducted a clinical trial testing therapeutic plasma exchange (TPE) combined with intravenous immunoglobulin (IVIG) as a strategy to reverse biological aging. Using multi-omics analysis — measuring molecular markers across the genome, proteome, and epigenome — they found participants receiving TPE plus IVIG experienced an average reduction in biological age of 2.6 years. This approach is grounded in the concept that aging factors circulating in blood can be diluted or replaced to restore a more youthful molecular profile. The results were published in the journal Aging Cell. This trial is among the first to demonstrate measurable biological age reversal in humans using a blood-based intervention, adding meaningful clinical evidence to a field that has largely relied on animal studies.
Detailed Summary
The idea that circulating factors in aging blood actively drive biological decline has gained significant traction over the past decade, largely from parabiosis experiments in animals. Now, a clinical trial from the Buck Institute offers the first robust human evidence that modifying the blood environment can measurably turn back biological age.
The trial tested therapeutic plasma exchange (TPE), a procedure that removes and replaces a portion of blood plasma, combined with intravenous immunoglobulin (IVIG). Researchers used multi-omics analysis — integrating data from epigenomic, proteomic, and other molecular layers — to assess changes in biological age before and after treatment.
Participants receiving the TPE plus IVIG combination showed the most pronounced effect, with biological age reduced by an average of 2.6 years. This multi-omics confirmation adds rigor beyond single-clock measurements, suggesting the rejuvenating signal is detectable across multiple biological systems simultaneously.
The implications are substantial. TPE is already an FDA-approved procedure used for autoimmune and neurological conditions, meaning its safety profile is well established. Pairing it with IVIG — which may help restore beneficial immune proteins removed during plasma exchange — could represent a near-term clinically translatable anti-aging protocol.
Caveats are important to acknowledge. The full study details, including sample size, control arm design, and duration of effect, are not available from the abstract and press release alone. It remains unknown how long biological age reductions persist, whether they translate into functional healthspan improvements, and what the optimal treatment frequency would be. Cost and accessibility of TPE also present real-world barriers. Nonetheless, this trial marks a meaningful step toward evidence-based blood-based rejuvenation therapies in humans.
Key Findings
- TPE plus IVIG reduced biological age by an average of 2.6 years in trial participants.
- The TPE plus IVIG combination outperformed other treatment arms in biological age reduction.
- Multi-omics analysis confirmed rejuvenation signals across multiple molecular layers, not just one clock.
- TPE is already FDA-approved for other conditions, suggesting a viable path to clinical translation.
- Results were published in Aging Cell, a peer-reviewed journal focused on aging biology.
Methodology
This was a clinical trial using therapeutic plasma exchange with and without IVIG across treatment groups. Biological age was assessed using multi-omics analysis integrating epigenomic and proteomic data. Full methodology including sample size, randomization, and blinding details are not available from the abstract and press release alone.
Study Limitations
This summary is based on the abstract and press release only; the full study methodology, sample size, control conditions, and statistical details were not accessible. The duration of the biological age reduction effect and whether it translates to clinical healthspan improvements remain unknown. Cost, accessibility, and insurance coverage of TPE represent significant practical barriers for most patients.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.